We first evaluated whether streptavidin labelling of the antibody and conjugation to Biotin-Saporin impaired the Her2 antigen binding capacity of the monoclonal antibody trastuzumab on Her2-high SKBR-3 breast cancer cells. This evidence concerns the gene ERBB2 and breast carcinoma.